David Sourdive

David Sourdive, born in Paris on December 26, 1966, has a PhD in Molecular Virology. He is Executive Vice President, Corporate Development for the biotechnology company Cellectis, which he cofounded in 1999 with André Choulika, the company’s Chief Executive Officer^[1]. He is also a Member of the Board of Medicen Paris Region, where he holds the post of Vice-President for Small and Medium-Sized Enterprises.

Biography

After graduating from the Ecole Polytechnique, in 1989, David Sourdive joined the Institut Pasteur, where he conducted research for a joint DEA (advanced postgraduate diploma) in General Virology and General Microbiology awarded by the University of Paris VII. It was also at the Institut Pasteur that he completed his PhD in Virology in 1995, which he followed with an AEA (Certificate of Advanced Studies)in Advanced Immunology one year later. His thesis on protein-protein interactions with the liver-specific transcription factor HNF1 was supervised by Professor Moshe Yaniv at the Institut Pasteur’s Oncogenic Virus Unit.

In 1997, after his PhD in Molecular Virology, David Sourdive joined one of the world’s leading antiviral immunology laboratories at Emory University (Atlanta, United States). Under the supervision of Professor Rafi Ahmed, he combined analysis techniques focusing on immune repertoires and vaccine antigens to elucidate the workings of antiviral cytotoxic immune memory in murine models. At the end of the following year, he headed a research group at the INSERM Unit on Gene Molecular Biology at the Institut Pasteur, supervised by Professor Philippe Kourilsky, and continued his research into immunological memory (CD8 + T-cells).

From 1989 to 1999, David Sourdive held various positions at the Defense Procurement Agency (DGA) of the French Ministry of Defense, particularly at Le Bouchet Research Center, where he was Director of the Biotechnologies Laboratory from 1998 to 1999. On December 20, 1999, he co-founded the company Cellectis with André Choulika, who he had met at the Institut Pasteur, and joined Class 17 for the Challenge+ program run by the prestigious Paris-based business school HEC, which provides support for the start-up of innovative high-technology companies.

Scientific publications

• Slifka, MK; Blattman, JN; Sourdive, DJ; Liu, F; Huffman, DL; Wolfe, T; Hughe, A; Oldstone, MB et al. (2003). "Preferential escape of subdominant CD8+ T cells during negative selection results in an altered antiviral T cell hierarchy". J Immunol. 170 (3): 1231–9. PMID 12538681. 
• Blattman, JN; Antia, R; Sourdive, DJ; Wang, X; Kaech, SM; Murali-Krishna, K; Altman, JD; Ahmed, R (2002). "Estimating the precursor frequency of naive antigen-specific CD8 T cells". J Exp Med. 195 (5): 657–64. PMID 11877489. 
• Blattman, JN; Sourdive, DJ; Murali-Krishna, K; Ahmed, R; Altman, JD (2000). "Evolution of the T cell repertoire during primary, memory, and recall responses to viral infection". J Immunol. 165 (11): 6081–90. PMID 11086040. 
• Zajac, AJ; Vance, RE,; Held, W; Sourdive, DJ; Altman, JD; Raulet, DH; Ahmed, R (1999). "Impaired anti-viral T cell responses due to expression of the Ly49A inhibitory receptor". J Immunol. 163 (10): 5526–34. PMID 10553080. 
• Murali-Krishna, K; Altman, JD; Suresh, M; Sourdive, D; Zajac, A; Ahmed, R (1998). "In vivo dynamics of anti-viral CD8 T cell responses to different epitopes. An evaluation of bystander activation in primary and secondary responses to viral infection". Adv Exp Med Biol. 452: 123–42. PMID 9889966. 
• Zajac, AJ; Blattman, JN; Murali-Krishna, K; Sourdive, DJ; Suresh, M; Altman, JD; Ahmed, R (1998). "Viral immune evasion due to persistence of activated T cells without effector function". J Exp Med. 188 (12): 2205–13. PMID 9858507. 
• Sourdive, DJ; Murali-Krishna, K; Altman, JD; Zajac, AJ; Whitmire, JK; Pannetier, C; Kourilsky, P; Evavold, B et al. (1998). "Conserved T cell receptor repertoire in primary and memory CD8 T cell responses to an acute viral infection". J Exp Med. 188 (1): 71–82. PMID 9653085. 
• Murali-Krishna, K; Altman, JD; Suresh, M; Sourdive, DJ; Zajac, AJ; Miller, JD; Slansky, J; Ahmed, R (1998). "Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection". Immunity 8 (2): 177–87. doi:10.1016/S1074-7613(00)80470-7. PMID 9491999. 
• Sourdive, DJ; Transy, C; Garbay, S; Yaniv, M (1997). "The bifunctional DCOH protein binds to HNF1 independently of its 4-alpha-carbinolamine dehydratase activity.". Nucleic Acids Res. 25 (8): 1476–84. doi:10.1093/nar/25.8.1476. PMC 146627. PMID 9092652. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=146627. 
• Sourdive, DJ; Chouard, T; Yaniv, M (1993). "The HNF1 C-terminal domain contributes to transcriptional activity and modulates nuclear localisation". C R Acad Sci III. 316 (4): 385–94. PMID 8402264. 
• Tronche, F; Rollier, A; Sourdive, D; Cereghini, S; Yaniv, M (1991). "NFY or a related CCAAT binding factor can be replaced by other transcriptional activators for co-operation with HNF1 in driving the rat albumin promoter in vivo". J Mol Biol. 222 (1): 31–43. PMID 1942067. 

See also

• Institut Pasteur
• Cellectis
• Meganuclease

References

1. ^ "Executive Committee". Cellectis. http://www.cellectis.com/about-us/governance/executive-committee. Retrieved september 25, 2011. 

External links

• Cellectis website
• Institut Pasteur website
• Medicen official website
• David Sourdive's brief biography on European Commission website
• David Sourdive's brief biography on the Reuters website

Persondata
Name	Sourdive, David
Alternative names
Short description	Businessperson
Date of birth	December 26, 1966
Place of birth	Paris, France
Date of death
Place of death